CD8A and neoplasm: These LNPs promoted the release of tumor-associated antigen and the activation of APCs, improving CD8+ T cells-mediated antitumor immunity.[93] In 2022, Yan et al. formulated resiquimod (R848) derived amino lipids into RAL-LNPs, such as RAL1 and RAL2 LNP.[94] Among them, RAL2-LNP delivered CD40 mRNA to DCs in vivo with high efficiency, facilitating DC maturation and inducing potent anti-tumor immune responses.